CNSX:ATT - Abattis Bioceuticals Stock Price, News, & Analysis

eye icon Add
Today's Range N/A
50-Day Range
MA: C$0.08
52-Week Range N/A
Average Volume1.42 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Abattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.

Industry, Sector and Symbol

Industry N/A



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive ATT News and Ratings via Email

Sign-up to receive the latest news and ratings for ATT and its competitors with MarketBeat's FREE daily newsletter.

Abattis Bioceuticals (CNSX:ATT) Frequently Asked Questions

What is Abattis Bioceuticals' stock symbol?

Abattis Bioceuticals trades on the CNSX under the ticker symbol "ATT."

What price target have analysts set for ATT?

1 analysts have issued 1 year price targets for Abattis Bioceuticals' stock. Their predictions range from C$0.30 to C$0.30. On average, they expect Abattis Bioceuticals' share price to reach C$0.30 in the next twelve months. View Analyst Price Targets for Abattis Bioceuticals.

What is the consensus analysts' recommendation for Abattis Bioceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abattis Bioceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abattis Bioceuticals.

Has Abattis Bioceuticals been receiving favorable news coverage?

Media stories about ATT stock have trended somewhat positive recently, according to InfoTrie. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Abattis Bioceuticals earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Abattis Bioceuticals.

What other stocks do shareholders of Abattis Bioceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abattis Bioceuticals investors own include Aphria (APHA), Surna (SRNA), CannTrust (CTST), HEXO (HEXO), Canopy Growth (WEED), Laird (LRD), Aurora Cannabis (ACBFF), Aurora Cannabis (ACB), MedReleaf (LEAF) and Hays (HAS).

Who are Abattis Bioceuticals' key executives?

Abattis Bioceuticals' management team includes the folowing people:
  • Robert Abenante CPA, President, Chief Executive Officer, Director (Age 33)
  • David Whitney, Chief Financial Officer
  • Rene David, Chief Operating Officer, Director
  • Christopher P. Cherry, Corporate Controller (Age 40)
  • Hugh Oswald, IR Contact Officer
  • Christina Boddy, Corporate Secretary
  • Peter Gordon, Director
  • James Irving, Director
  • Shuang Xie, Director
  • Guy P. Dancosse QC, Independent Director

What is Abattis Bioceuticals' official website?

The official website for Abattis Bioceuticals is

How can I contact Abattis Bioceuticals?

Abattis Bioceuticals' mailing address is 224-970 Burrard St, VANCOUVER, BC V6Z 2R4, Canada. The company can be reached via phone at +1-604-3360881.

MarketBeat Community Rating for Abattis Bioceuticals (CNSX ATT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  72 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  149
MarketBeat's community ratings are surveys of what our community members think about Abattis Bioceuticals and other stocks. Vote "Outperform" if you believe ATT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/16/2019 by Staff

Featured Article: Technical Analysis

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel